WO1988008842A3 - 2-ACYLPYRIDIN-alpha-(N)-HETARYLHYDRAZONES SUBSTITUEES ET MEDICAMENTS CONTENANT CELLES-CI - Google Patents

2-ACYLPYRIDIN-alpha-(N)-HETARYLHYDRAZONES SUBSTITUEES ET MEDICAMENTS CONTENANT CELLES-CI Download PDF

Info

Publication number
WO1988008842A3
WO1988008842A3 PCT/DE1988/000289 DE8800289W WO8808842A3 WO 1988008842 A3 WO1988008842 A3 WO 1988008842A3 DE 8800289 W DE8800289 W DE 8800289W WO 8808842 A3 WO8808842 A3 WO 8808842A3
Authority
WO
WIPO (PCT)
Prior art keywords
hetarylhydrazones
acylpyridin
alpha
substituted
containing same
Prior art date
Application number
PCT/DE1988/000289
Other languages
German (de)
English (en)
Other versions
WO1988008842A2 (fr
Inventor
Klaus-Juergen Schapper
Joachim K Seydel
Original Assignee
Deutsches Aussaetzigen Hilfswe
Schapper Klaus Juergen
Joachim K Seydel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Aussaetzigen Hilfswe, Schapper Klaus Juergen, Joachim K Seydel filed Critical Deutsches Aussaetzigen Hilfswe
Priority to DE8888904462T priority Critical patent/DE3874671D1/de
Priority to AT88904462T priority patent/ATE80624T1/de
Publication of WO1988008842A2 publication Critical patent/WO1988008842A2/fr
Publication of WO1988008842A3 publication Critical patent/WO1988008842A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Des 2-acylpyridin-alpha-(N)-hetarylhydrazones substituées conviennent comme substances actives pour le traitement de maladies microbiennes, en particulier mycobactériennes, pour le traitement de la malaria ou de tumeurs malignes. Ces composés ont une efficacité synergétique marquée en combinaison avec des inhibiteurs de la folatsynthase, de la reductase d'acide dihydrofolique, de la synthèse d'ADN et de la synthèse d'ARN.
PCT/DE1988/000289 1987-05-14 1988-05-14 2-ACYLPYRIDIN-alpha-(N)-HETARYLHYDRAZONES SUBSTITUEES ET MEDICAMENTS CONTENANT CELLES-CI WO1988008842A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE8888904462T DE3874671D1 (de) 1987-05-14 1988-05-14 Substituierte 2-acylpyridin-alpha-(n)-hetarylhydrazone sowie diese enthaltende arzneimittel.
AT88904462T ATE80624T1 (de) 1987-05-14 1988-05-14 Substituierte 2-acylpyridin-alpha-(n)hetarylhydrazone sowie diese enthaltende arzneimittel.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873716131 DE3716131A1 (de) 1987-05-14 1987-05-14 Substituierte 2-acylpyridin-(alpha)-(n)-hetarylhydrazone sowie diese enthaltende arzneimittel
DEP3716131.8 1987-05-14

Publications (2)

Publication Number Publication Date
WO1988008842A2 WO1988008842A2 (fr) 1988-11-17
WO1988008842A3 true WO1988008842A3 (fr) 1988-12-01

Family

ID=6327540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1988/000289 WO1988008842A2 (fr) 1987-05-14 1988-05-14 2-ACYLPYRIDIN-alpha-(N)-HETARYLHYDRAZONES SUBSTITUEES ET MEDICAMENTS CONTENANT CELLES-CI

Country Status (5)

Country Link
US (2) US4997835A (fr)
EP (1) EP0313630B1 (fr)
AT (1) ATE80624T1 (fr)
DE (2) DE3716131A1 (fr)
WO (1) WO1988008842A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3716131A1 (de) * 1987-05-14 1988-12-01 Forsch Borstel Inst Fuer Exper Substituierte 2-acylpyridin-(alpha)-(n)-hetarylhydrazone sowie diese enthaltende arzneimittel
US6229001B1 (en) 1997-01-03 2001-05-08 Southern Research Institute Mycobacterium fol a gene that encodes for the enzyme dihydrofolate reductase
FR2768736B1 (fr) * 1997-09-24 2000-05-26 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US6878729B2 (en) * 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
WO2007104695A1 (fr) * 2006-03-15 2007-09-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Dérivés de quinolin-4-ylhydrazine en tant qu'agents antimalariaux
WO2008021211A2 (fr) * 2006-08-10 2008-02-21 Fred Hutchinson Cancer Research Center Compositions et procédés de modulation de l'apoptose dans des cellules surexprimant les protéines membres de la famille bcl-2
EP2311457A1 (fr) * 2009-10-19 2011-04-20 Forschungszentrum Borstel Compositions pharmaceutiques pour traiter les infections avec des mycobactéries résistantes aux médicaments
CN102060757B (zh) * 2010-12-14 2013-05-22 聊城大学 酰腙类Schiff碱化合物及其制备方法与应用
CZ303748B6 (cs) * 2011-10-11 2013-04-17 Vysoká skola chemicko - technologická v Praze Ftalazin-1-ylhydrazony a jejich pouzití k lécbe nádorových onemocnení
PT106652A (pt) * 2012-11-20 2014-05-20 Tecnimede Sociedade Tecnico Medicinal S A Piridil hidrazonas para o tratamento de tuberculose e doenças relacionadas
CN105418496B (zh) * 2015-09-23 2018-05-29 浙江工业大学 一种3-氯-2-肼基吡啶衍生物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3371090A (en) * 1964-09-16 1968-02-27 Pfizer & Co C Novel antibacterial agents
JPS55151570A (en) * 1979-05-15 1980-11-26 Takeda Chem Ind Ltd Pyrimidine derivatives, their preparation and antimicrobial for agriculture
JPS5714579A (en) * 1980-07-01 1982-01-25 Teikoku Hormone Mfg Co Ltd Novel hydroxybenzylidenehydrazinophthalazine derivative
ES511134A0 (es) * 1981-04-06 1983-02-16 Hexachimie "procedimiento de preparacion de nuevos derivados de la hidrazina, utiles como fungicidas y bactericidas".
CH656629A5 (de) * 1981-08-08 1986-07-15 Sandoz Ag Tetrakisazoverbindungen mit brueckenglied, verfahren zur herstellung und verwendung.
US4670437A (en) * 1985-09-11 1987-06-02 Eli Lilly And Company Antiviral pyridazine hydrazones
DE3716131A1 (de) * 1987-05-14 1988-12-01 Forsch Borstel Inst Fuer Exper Substituierte 2-acylpyridin-(alpha)-(n)-hetarylhydrazone sowie diese enthaltende arzneimittel
EP0362135A3 (fr) * 1988-09-28 1990-10-17 Ciba-Geigy Ag Parasiticide

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, Band 84, 9, 1. Marz 1976, (Columbus, Ohio, US), C.F. Bell et al.: "Proton NMR spectra of E- and Z-pyridine-2-carboxaldehyde 2'-pyridyl-hydrazone and related compounds", Seite 410 *
Chemical Abstracts, Band 91, Nr. 21, 19. November 1979 (Columbus, Ohio, US), C. Pellerano et al.: "Some hydrazino-quinoline derivatives: 2-quinolylhydra-zones. VI.", siehe Seite 645 *
Il Farmaco, Band XL, Nr. 9, September 1985, C. Pellerano et al.: "Sistemi chelanti tridentati N-N-N quali potenziali agenti antitumorali", Seiten 645-654 *
J. Inorg. Nucl. Chem., Band 43, 1981, Pergamon Press Ltd (GB), A.E. Mihkelson: "Reactions of Pd(II) with a series of potentially tridentate nitrogen ligands-I", Seiten 123-126 *
J. Protozool., Band 29, nr. 1, 1982, The Society of Protozoologists, a. Shapiro et al.: "In vivo and in vitro activity by diverse chelators against Trypanosoma brucei brucei", Seiten 85-90 *

Also Published As

Publication number Publication date
US5084458A (en) 1992-01-28
EP0313630A1 (fr) 1989-05-03
DE3874671D1 (de) 1992-10-22
US4997835A (en) 1991-03-05
DE3716131A1 (de) 1988-12-01
WO1988008842A2 (fr) 1988-11-17
EP0313630B1 (fr) 1992-09-16
ATE80624T1 (de) 1992-10-15

Similar Documents

Publication Publication Date Title
AU7585498A (en) Inhibition of p38 kinase activity by aryl ureas
CA2148928A1 (fr) Derives pyridine pharmacologiquement actifs ainsi que leurs procedes de preparation
MY120235A (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives
AU6194694A (en) Nor-bile acid derivatives, processes for their preparation and the use of these compounds as medicaments
CA2315647A1 (fr) Inhibition de l'activite de p38 kinase au moyen d'urees heterocycliques aryle et heteroaryle substituees
AU7031500A (en) Therapeutic quinazoline compounds
CA2436799A1 (fr) Combinaisons de medicaments (par exemple de chlorpromazine et de pentamidine) pour le traitement de troubles neoplasiques
WO1988008842A3 (fr) 2-ACYLPYRIDIN-alpha-(N)-HETARYLHYDRAZONES SUBSTITUEES ET MEDICAMENTS CONTENANT CELLES-CI
CA2145093A1 (fr) Inhibiteur therapeutique des cellules musculaires lisses
WO2000006134A3 (fr) Utilisation de l-carnitine et de ses derives alkanoyl dans la preparation de medicaments a action anticancereuse
MX9606744A (es) Acidos hidroxamicos sustituidos por sulfonamido arilico como inhibidores de metaloproteinasa de matriz.
EP0379806A3 (fr) Pyrimidines et leurs sels acceptables en pharmacie, et leur utilisation comme médicaments
EP1140840A4 (fr) Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
GEP20022786B (en) Purine Inhibitors of Cyclin Dependent Kinase 2 and 1kB-a
IL136738A0 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
EP1820862A3 (fr) Mise à l'échelle de polarisation de couple d'un côté sur l'autre afin d'améliorer la dérive dans une transmission à quatre roues motrices programmable
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
SI0929565T1 (en) Nitrate esters of corticoid compounds and pharmaceutical applications thereof
WO1993019720A3 (fr) Composes
WO2005014572A8 (fr) Derives de pyrimidylpyrrole pouvant etre utilises comme inhibiteurs de kinases
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
WO2001072685A3 (fr) Polyamine analogues, agents cytotoxiques
GB9907571D0 (en) Compounds
AU2002342808A1 (en) Extract with anti-tumor and anti-poisonous activity
WO2001041747A3 (fr) Preparation pharmaceutique pour traiter des affections tumorales

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1988904462

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1988904462

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1988904462

Country of ref document: EP